EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Agile Therapeutics's enterprise value is $2.36 Mil.
Agile Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $19.59 Mil. Therefore, Agile Therapeutics's EV-to-Revenue for today is 0.12.
The historical rank and industry rank for Agile Therapeutics's EV-to-Revenue or its related term are showing as below:
AGRX'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.02 Med: 0.72 Max: 342.92
Current: 0.12
During the past 12 years, the highest EV-to-Revenue of Agile Therapeutics was 342.92. The lowest was 0.02. And the median was 0.72.
AGRX's EV-to-Revenue is ranked better than 98.05% of 1025
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs AGRX: 0.12
The historical data trend for Agile Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Agile Therapeutics's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Agile Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agile Therapeutics's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Agile Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Agile Therapeutics's EV-to-Revenue falls into.
Agile Therapeutics's current Enterprise Value is $2.36 Mil.
Agile Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.59 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agile Therapeutics's share price for today is $0.40.
Agile Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.76.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agile Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Agile Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Agile Therapeutics (Agile Therapeutics) Business Description
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AGRX has been successfully added to your 